drug

Sensory Based remediation paradigm

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
BEHAVIORAL
Pre-approval / investigational in the US
Developed by Nathan Kline Institute for Psychiatric Research
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
BEHAVIORAL

Indications

Trials

1
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
NCT01474395Phase 2Unknown

KOLs & investigators

1
Joshua T Kantrowitz, MDKOL score 16

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Nathan Kline Institute for Psychiatric Research
company
trial
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Joshua T Kantrowitz, MD
KOL score 16
person